Howe & Rusling’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-802
Closed -$15K 951
2020
Q4
$15K Buy
802
+268
+50% +$5.6K ﹤0.01% 434
2020
Q3
$13K Hold
534
﹤0.01% 400
2020
Q2
$13K Buy
+534
New +$13.2K ﹤0.01% 395

Other funds holding BTAL

Howe & Rusling's BTAL Position: Q1 2021 in Review

Howe & Rusling sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q1 2021, closing a stake of 802 shares — an estimated $15K sold.

Howe & Rusling first reported a position in BTAL in Q2 2020 and held it in 3 quarters. The position peaked at $15K in Q4 2020. 32 funds tracked by Wall St. Rank hold BTAL as of Q1 2021.

  • Howe & Rusling reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q1 2021 after selling out during the quarter.
  • Howe & Rusling sold 802 AGF US Market Neutral Anti-Beta Fund shares in Q1 2021, an estimated $15K.
  • Howe & Rusling first reported a position in AGF US Market Neutral Anti-Beta Fund in Q2 2020 and held it in 3 quarters.
  • Howe & Rusling's AGF US Market Neutral Anti-Beta Fund position peaked at $15K in Q4 2020.
  • 32 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q1 2021.

Based on Howe & Rusling's 13F filing for Q1 2021, filed 13 May 2021.